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INTRODUCTION  
Cirrhosis (chronic liver disease) represents a disorder which causes progressive 
hepatic fibrosis characterized by distorted liver architecture and the formation of 
nodules which are regenerative. Cirrhosis of any cause is usually not reversible 
when it is in the advanced stages at which the only option available may be liver 
transplantation. However, in recent times reversal of cirrhosis  has been reported in 
several forms of liver disease following treatment of the underlying cause if 
detected in its early stages. Patients with cirrhosis are prone to a variety of 
complications. 
Some of the common cause for cirrhosis are 
1. Alcoholic liver disease 
2. Viral hepatitis B & C 
3. Autoimmune hepatitis 
4. Hereditary hemochromatosis 
5. Wilson’s disease 
6. Alfa-1 antitrypsin deficiency 
7. Nonalcoholic fatty liver disease 
2 
 
8. Primary biliary cirrhosis 
9. Primary sclerosing cholangitis 
 
Complications of cirrhosis include (20) 
1. Variceal bleed 
2. Hepatic encephalopathy 
3. Ascites 
4. Spontaneous bacterial peritonitis 
5. Hepatorenal syndrome 
6. Hepatopulmonary syndrome 
7. Hepatocellular carcinoma 
 
Metabolic complications commonly encountered in patients with chronic liver 
disease are malnutrition, hyponatremia and metabolic bone disease. 
Common chronic cholestatic liver disorders are primary sclerosing cholangitis and 
primary biliary cirrhosis. Hepatic osteodystrophy is known to occur in chronic 
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cholestatic liver diseases. Osteopenic bone disease with fracturing is a 
complication of chronic cholestatic liver diseases (20). But data regarding the 
occurrence of metabolic bone disease (hepatic osteodystrophy) in the setting of non 
cholestatic chronic liver disease is scanty.  
 
The development of metabolic bone disease in patients with primary biliary 
cirrhosis has, in most reports, been directly related to the duration and severity of 
PBC and to the intensity and duration of jaundice . However, the mechanisms 
which cause osteodystrophy in patients with PBC are not well understood. The 
plasma concentrations of vitamin D metabolites and calcium are usually normal. 
Biochemical and bone histomorphometric studies suggest that these patients, 
particularly in the precirrhotic stage, have a "low-turnover" osteoporosis, in which 
bone formation is inhibited and bone resorption is low or normal, although the 
mechanism(s) causing these changes are not known (19) .  
 
It was initially proposed that decreased bile salt flow, leading to malabsorption of 
vitamin D, was responsible for the development of osteoporosis. However, this 
hypothesis is most likely incorrect given the observations that the plasma levels of 
calcidiol (25-hydroxyvitamin D) and calcitriol (1,25 dihydroxyvitamin D) are 
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normal in PBC patients with osteoporosis and that vitamin D replacement in the 
group of cases with decreased plasma concentrations will not improve the severity 
of osteodystrophy. 
 
 
Genetic  causes for osteopenia in PBC like polymorphisms in vitamin D receptor (7) 
, polymorphisms in IGF-1 gene and polymorphisms in collagen type Ia gene have 
been proposed, but now of the genetic variations were proven to be associated in 
most of the studies.  
The diagnosis and severity assessment of osteodystrophy is done by dual energy x-
ray absorptiometry (DEXA) (14) . It is a non invasive method which measures the 
bone mineral density. Patients are assisgned T-score and Z- score which are 
standard deviations below the peak and normal values. This is very useful test to 
screen the patients for osteodystrophy. 
Data regarding the occurrence of metabolic bone disease (hepatic osteodystrophy) 
in the setting of non cholestatic chronic liver disease is scanty.  
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AIM OF THE STUDY 
“To study the frequency of metabolic bone disease in noncholestatic chronic liver 
disease” 
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LITERATURE REVIEW 
Osteodystrophy  is a complication in patients with chronic hepatopathy, especially 
in those affected by chronic cholestasis. Metabolic bone disease usually manifests 
as osteopenia and osteoporosis. This bone disorder must be evaluated and detected 
early in all cirrhotic patients  to minimize the risk of fractures and improve the 
quality of life. 
 
EPIDEMIOLOGY 
Various international studies have shown the overall incidence of metabolic bone 
disease in cirrhosis to be  between  11% to 48%,and   fracture risk due to the bone 
disease to be between  3%-44%. 
 
Some of the studies  which has shown the prevalence are 
1.  Goral et al. 2010 –  frequency of osteodystrophy was 37% in patients 
with cirrhosis of mixed etiology  
2. Wariaghli et al. 2010 – frequency of osteodystrophy was 45.3% in 
patients with cirrhosis of mixed etiology  
3. Loria et al. 2010 – frequency of osteoporosis was 14% and osteopenia 
was 26% in patients with cirrhosis of viral and alcohol etiology 
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4. Sokhi et al. 2004 – frequency of osteoporosis was 11.5% and osteopenia 
was 34.6% in patients cirrhosis of mixed etiology 
 
Chronic liver diseases which are known to cause hepatic osteodystrophy include, 
cholestatic liver diseases like primary biliary cirrhosis and primary sclerosing 
cholangitis (20). Hepatic osteodystrophy can also occur in alcoholic cirrhosis and 
hemochromatosis. 
 
PATHOGENESIS 
The pathogenesis of hepatic osteodystrophy in patients with liver cirrhosis has not 
been completely understood. Several factors which includes- decreased bone 
formation and increased bone resorption has been recognized in liver cirrhosis. 
Studies have shown that increase in proinflammatory cytokines, low insulin-like 
growth factor, and low vitamin K lead to alterations in bone metabolism. 
Cytokines which are increased in cirrhosis are IL-1, IL-6 and TNF-alfa (17). Serum 
osteocalcin levels decreases depending on reduction of osteoblast function. A 
decrease in serum osteocalcin levels and an increase in deoxypyridinoline (DPD) 
level have been observed in chronic liver disease which is the reason for the low 
turnover of bone mass. 
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Other factors responsible for reduced bone mineral deposition are 
 
1. Vitamin K deficiency – is required for osteoblasts to synthesize osteocalcin-
bone matrix protein. VitaminK deficiency leads to osteopenia in primary 
biliary cirrhosis and by supplementing it bone loss can be prevented (7) . 
2. IGF-1 deficiency – is required for osteoblast differentiation and prolif-
eration. IGF-1  deficiency occurring  in cirrhosis and cholestatic liver 
disease  cause osteoblast dysfunction and osteopenia (17) . 
3. Hyperbilirubinemia- rise in indirect hyperbilirubinemia has shown impair 
osteoblast function in animal models (7) . But this is not proven in human 
studies. 
 
 
ROLE OF CYTOKINE IN HEPATIC OSTEODYSTROPHY 
 
Interleukin 1, Interleukin 6, TNF-alfa which is increased in chronic liver disease 
activates receptor activator of nuclear factor κB ligand/osteoprotegerin, which 
regulates bone formation by modulating osteoclast activity. Receptor activator of 
nuclear factor κB ligand/osteoprotegerin is upregulated in chronic liver disease 
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which is activated by the increased cytokines and cause increased bone resorption 
(17) . 
  
Factors which increase the risk of osteodystrophy in cirrhotic patients include (7) 
1. Hypogonadism 
2. Vitamin D deficiency 
3. Alcohol consumption  
4. Chronic steroid treatment  
5.  Low body mass index 
 
Contribution of vitamin D 
Vitamin D has a variety of actions on minerals like calcium, phosphate, and bone 
metabolism. Vitamin D has an important biological effect on the enterocyte to 
promote differentiation and causes the intestinal absorption of calcium and 
phosphorus, which in turn promote bone mineralization. In high vitamin D 
concentrations and when there is calcium and phosphate deficiency, it also causes 
stimulation of bone resorption, which helps in the maintaince of supply of these 
ions to other tissues (6) . 
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Vitamin D is synthesized in the skin with exposure of ultraviolet rays from the sun; 
ultraviolet rays convert 7-dehydrocholesterol to vitamin D. Anyone with reduced  
exposure to the sun is prone to vitamin D deficiency. Calcidiol, is formed in the 
liver before being converted in the kidneys into metabolic active vitamin D 
(calcitriol).  
 
Gastrointestinal causes of vitamin D deficiency include gastrointestinal 
malabsorption, associated with disorders of the small intestine, pancreatic diseases 
resulting in decreased absorption of vitamin D and hepatobiliary disease causes 
depletion of endogenous 25OHD stores due to abnormal enterohepatic circulation. 
Malabsorption of vitamin D results as a consequence of steatorrhea, which reduces 
fat emulsification and chylomicron-facilitated absorption (6) . Vitamin D deficiency 
may be associated with rickets or osteomalacia. Patients affected are asymptomatic 
or may exhibit  a reduction in bone volume rather than causing  defective bone 
mineralization. 
 
 
In  liver failure, the levels of 25-OH vitamin D can be reduced due to impaired 
synthesis. However, liver function needs to be severely compromised for it to 
cause  reduced 25-OH vitamin D synthesis (7) .  
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Subclinical vitamin D insufficiency  is common in the setting of chronic liver 
disease  and could contribute to the formation of osteoporosis or osteopenia by 
decreasing absorption of calcium (6). 
 
Vitamin D deficiency  is usually  associated with secondary hyperparathyroidism, 
and there is increased bone turnover and accelerated loss of bone mass. Factors 
which contribute to vitamin D deficiency include  Intestinal malabsorption, altered 
enterohepatic circulation of vitamin D and reduced skin synthesis in patients with 
jaundice. 
 
CLINICAL FEATURES  
Patients with metabolic bone disease are usually symptomatic and they are picked 
up during routine screening. 
When symptoms do occur, they are related to fractures. The most common 
fractures are vertebral fractures, two-thirds of which are asymptomatic and are 
diagnosed as incidental findings on a chest or abdominal x-ray. In some patients, 
vertebral fractures may result in loss of height, kyphosis, or acute back pain. Other 
fractures seen in patients with osteoporosis include hip fractures and distal radius 
fractures 
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FRACTURE RISK ASSESSMENT 
Facture risk has to determined in patients with metabolic bone disease irrespective 
of the cause. Patients with osteoporosis and osteopenia are at increased risk for 
facture (3). Risk factors independent of bone mineral density include 
1. Previous history of fracture 
2. Increased age 
3. Long-term glucocorticoid therapy 
4. Low body weight  < 58 kg 
5. Family history of hip fracture 
6. Smoking  
7. Excess alcohol intake 
 
 
DIAGNOSIS OF METABOLIC BONE DISEASE 
 Bone mineral density determines the bone strength. Determinants of bone 
strength, which are not  dependent on bone mineral density are bone turn over, 
microarchitecture of bone like trabacular thickness, cortical thickness and cortical 
porosity, matrix properties and mineralizaton.  
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Investigation for bone strength will give an insight on the pathogenesis of 
osteoporosis and osteopenia and gives a better understanding on the treatment 
given for osteoporosis. Investigations like micro CT and MRI are being developed 
which can discern individual trabeculae are being developed. With these 
investigations fracture risk can be accurately gauged. As of now the gold standard 
for the diagnosis of metabolic bone disease is by DEXA scan (6). 
 Bone mineral density testing — BMD testing is the most commonly used 
clinical test to diagnose osteoporosis, osteopenia, predict the risk for fracture, and 
monitor response to therapy. BMD testing can be done on various sites of the body 
and predict fracture risk. Dual-energy x-ray absorptiometry (DEXA SCAN) of the 
spine, hip, and forearm is the method for diagnosis of osteoporosis (14). Serial 
monitoring of bone mineral density over a period is essential because 
1. There has been a strong correlation between bone mineral density measured 
by DEXA scan and mechanical strength. 
2. Studies have shown relationship between bone mineral density by DEXA 
scan and fracture risk. 
3. Randomized clinical trails have shown drug therapy based on the bone 
mineral density measurement has reduced fracture risk. 
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4. Accuracy and precision of bone mineral density measured by DEXA scan is 
very good. 
5. Radiation exposure with DEXA scan is very low. 
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Dual-energy x-ray absorptiometry technology — A typical DEXA scan machine 
consists of a padded table on which the patient should lie and a movable C-arm 
with an x-ray tube under the patient and a detector above the patient. The x-ray 
tube, which is below the patient generates photon beams of two different energy 
levels, for which is called "dual-energy" source. A collimator below the table 
controls the scatter of the photons and directs the photons towards the area of 
interest. The difference in attenuation that is the reduction in intensity of the two 
photon beams as they go through body tissue of variable composition and  
distinguishing bone from soft tissue and allows quantification of bone mineral 
density. Denser and thicker tissue contains more electrons and will not allow many 
photons to pass through to the detector. A computer which is specially designed 
with its proprietary software designed by each manufacturer forms a complete 
DEXA scan. 
Radiation exposure to the patient is very minimal, usually of a similar magnitude 
to daily background radiation. Radiation which is scattered beyond the edge of the 
DEXA table is negligible. Shielding of the technologist or the room is not 
necessary. But as a safety precaution, the technologist doing the DEXA scan 
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should typically not sit within three feet of the table edge when the patient is being 
scanned. 
DEXA measures bone mineral content (in gms) and bone area (in square 
centimeters), then calculates "areal" BMD in g/cm2 by dividing bone mineral 
content and bone area. T-score, the value used for diagnosis of osteoporosis, is 
calculated by subtracting the mean BMD of a young-adult reference population 
from the patient's BMD and dividing by the standard deviation (SD) of young-
adult population. Z-score, used to compare the patient's BMD to a population of 
peers, is calculated by subtracting the mean BMD of an age-, ethnicity-, and sex-
matched reference population from the patient's BMD and dividing by the SD of 
the reference population. The mean BMD and SD of the reference populations 
used for these calculations is a critical variable in the determination of T-scores 
There are significant differences in the technologies used by different 
manufacturers and sometimes different models of DEXA made by the same 
manufacturer. Manufacturers use different methods for creating dual photon beams 
(eg, K-edge filtering and voltage switching), different bone edge detection 
algorithms, different assumptions on body size and tissue composition, different 
calibration, and different types of photon detectors. Photon beams have different 
configurations, eg, pencil beam and fan beam. The bone regions of interest (ROI) 
measured may be different, especially so with the femoral neck. The reference 
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databases used to calculate T-scores and Z-scores may be different. For all of these 
reasons, it is not possible to make quantitative comparisons of BMD measured on 
different instruments, especially those made by different manufacturers, unless a 
cross-calibration study has been done 
 
 
Figure 1 – dual energy x-ray absorptimetry. 
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Other methods to analyze bone mineral density 
1. Quantitative CT – cortical and trabecular bone can be assessed by 
determining the volume of bone density. It can measure the bone density of 
hip and spine. This test can be used to assess the treatment reponse and is 
also being used is research setup. This method is ot used for routine 
screening. Drawbacks of this test are, it cannot assess the risk of fracture and 
is a very expensive test. 
2. Ultrasound - Patients at risk for osteoporosis can be identified with use of 
quantitative ultrasound, which is a reasonable predictor of fracture risk.  This 
method can be used in mass screening setup and there is no risk of radiation. 
But ultrasound threshold cutoff for DEXA score has not been having good 
sensitivity and specificity. This test cannot be used as confirmatory test and 
always one has do DEXA scan in suspected patients to confirm low bone 
mineral density. Since with ultrasound only the peripheral sites can be 
measured it cannot be used as a tool for follow up of patients who are on 
therapy. In current clinical practice quantitative ultrasound can only be used 
in mass screening and clinical research. 
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SITE OF MEASUREMENT OF BONE MINERAL DENSITY 
Most common site for measurement of bone mineral density are HIP and SPINE. 
Spine measurement is more accurate and fracture risk can be assessed more 
precisely. In patients with cirrhosis and ascites, measurement of bone mineral 
density of spine can be falsely positive, due to the fluid in the abdomen. In these 
patients with ascites measurement of  bone mineral density from the hip will be 
useful to assess the risk of fracture (8).  
Other sites of bone mineral density measurement include the peripheral site like 
calcaneum and wrist. Methods by which the measurement can be done are portable 
DEXA scan, x-ray absorptiometry and ultrasound. 
These methods by which the peripheral bone mineral density is measured are not 
validated and the only method validated by the WHO is DEXA scanning of the hip 
or spine. Only place where the peripheral measurement is used is, in the setting of 
mass screening. 
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SCREENING FOR BONE MINERAL DENSITY LOSS  
Screening for osteoporosis has to be done in all patients with chronic cholestatic 
disease. DEXA scan should be advised once a year and follow up of patients on 
treatment for osteoporosis or osteopenia can be done with DEXA scan every 2 
years (16). 
There are few studies showing the incidence of osteoporosis in chronic liver 
disease with varying etiology to be between 11 to 48%. So, screening for 
osteodystrophy in cirrhotic patients can reduce the fragile fractures and can lead to 
improvement in the quality of life. 
Post liver transplant patients are prone for bone disease and increased risk of 
fractures, so it is advisable to screen all patients awaiting liver transplant, in order 
to give them the appropriate treatment and reduce fracture risk. 
 
TREATMENT   
General treatment includes non pharmacologic measures like diet rich in vitamin 
D, light exercises and smoking cessation.  
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Smoking is major risk factor for osteodystrophy and smoking cessation 
considerably decreases the risk of fractures. 
Calcium and vitamin D supplementation should be done to maintain bone density. 
Calcium in the dose of 1000 mg /day and the dose of vitamin D is 800 U/day (21).  
 
Pharmacological therapy for metabolic bone disease  
Bisphosphonates — Alendronate (10 mg/day or 70 mg once weekly [orally]) or 
risedronate (5 mg/day, 35 mg once weekly, or 150 mg once monthly), and 
ibandronate (150 mg once monthly [orally] or 3 mg intravenously every three 
months) (22). 
Zoledronic acid (ZA), 5 mg administered intravenously (IV) once yearly, is also 
effective for osteodystrophy.  
Severe esophagitis can occur with this group of drugs and it can be prevented by 
taking large amounts of water and being upright for 1 hour. 
Bisphosponates are the main treatment in patients with severe metabolic bone 
disease , even though there is very limited data on its use in cirrhosis. 
Selective estrogen receptor modulators — Raloxifene (22) is a tissue selective 
estrogen receptor modulator (SERM) that is used for the prevention and treatment 
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of osteoporosis. It increases bone mineral density and reduces the risk of vertebral 
fractures. Raloxifene also appears to lower the risk of breast cancer, does not 
stimulate endometrial hyperplasia or vaginal bleeding, and increases the risk of 
venous thromboembolism. Although it decreases serum total and low-density-
lipoprotein (LDL) cholesterol concentrations, raloxifene does not appear to affect 
the risk of coronary heart disease. 
 
Raloxifen is one of the first-line drugs for prevention of osteoporosis. However, it 
is somewhat less effective than estrogen and bisphosphonates, although direct 
fracture prevention comparisons are lacking. There are nonskeletal considerations 
with raloxifene that may play an important role in the selection of patients for 
preventive therapy. Raloxifene reduces breast cancer risk but increases 
thromboembolic events and hot flashes. 
 
Parathyroid hormone — Parathyroid hormone (PTH) seems an unlikely 
candidate for the treatment of osteoporosis because of its well-described 
deleterious effect on bone. However, intermittent administration of recombinant 
human PTH (both full-length 1-84 or fragment 1-34) stimulates bone formation 
more than resorption and is effective for fracture reduction in women with 
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osteoporosis. This topic is reviewed in detail elsewhere.PTH is also effective in 
men with osteoporosis. 
Some of the newer medications which are used to treat bone mineral loss include 
1. Denosumab-which is a monoclonal antibody directed against the receptor 
responsible for bone resorption. Osteoclasts are inhibited by this medication. 
2. Strontium ranelate – it is drug which is being tried in animal models and it 
acts by decreasing bone resorption. Based upon changes in markers of bone 
formation and resorption in postmenopausal women with osteoporosis, it 
appears to have a modest antiresorptive effect, with little effect on bone 
formation  
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MATERIAL  AND METHODS 
Study design – cross sectional study 
Subjects : 
32 patients with the diagnosis of non cholestatic liver disease attending our 
department were included and 10 healthy subjects were taken as controls were 
taken in this study. 
 
All the patients and controls were explained in detail about the study, and an 
informed consent was obtained. 
 
EXCLUSION CRITERIA 
1. Patients with cholestatic liver disease 
2. Patients who were on calcium supplements and vitamin D 
3. Patients on medications which affect bone mineral density 
4. Postmenopausal women 
5. Patients with coexistent chronic kidney disease 
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Patients enrolled in the study were evaluated for the cause for liver disease. 
Evaluation included 
1. Hepatitis B 
2. Hepatitis C 
3. Wilson’s disease 
4. Alcoholic liver disease 
5. Autoimmune hepatitis 
6. Iron studies 
 
Biochemical analysis 
Blood for biochemical analysis was drawn from all patients enrolled in the study. 
After an overnight fast for 10 hours, blood for analysis was drawn in the morning. 
Biochemical analysis included liver function test, prothrombin time, renal function 
test, serum calcium, serum phosphosus, parathyroid hormone and vitamin D. 
 
Liver function test, renal function test and prothrombin time analysis were done by 
automated method. Calcium estimation was done by arsenazo III method,and 
phosphorus was estimated by ammonium molybdate method. Parathyroid hormone 
and vitamin D were estimated by chemiluminescence immumunoassay (CIA). 
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BONE MINERAL DENSITY MEASUREMENT 
All patients and controls included in the study were subjected to bone mineral 
density measurement by dual energy x-ray absorptiometry (DEXA). Dual energy 
x-ray absorptiometry was done by using HOLOGIC-QDR4500 machine. 
 
Patients and controls were classified as having normal BMD or osteopenia or 
osteoporosis using the WHO criteria. 
 
SEVERITY OF LIVER DISEASE 
Severity assessent of the liver disease in patients with cirrhosis was done by Child 
Pugh score and Model for End Stage Liver Disease (MELD) scores (20).  
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Figure 2 – HOLOGIC-QDR 4500 dual energy x-ray absorptiometry. 
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Observation and Results 
 
Sex distribution 
In the study, there were 32 patients with cirrhosis and 10 normal controls. Out of 
the 32 patients, there was 22 male patients (68.8%)  and 10 female patients 
(31.3%). In the control group, there were 6 males (60%) and 4 females (40%). 
Table 1 
 
 
 
 
 
 
 
 
 
 
 
 
Sex 
Group Total 
 
Cases Controls 
N % N % N % 
Male 22 68.8 6 60.0 28 66.7 
Female 10 31.3 4 40.0 14 33.3 
Total 32 100.0 10 100.0 42 100.0 
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Chart 1 
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Age group 
 
Average  age of the patients was 38.97 yrs. 
Average  age ot the controls was 42.50 yrs. 
 
 
Chart 2 
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Comparison of biochemical variables between cases and controls 
Mean bilirubin level in the cirrhosis group was 1.31 and in the control group it was 
0.88. 
 
Chart 3 
Mean alkaline phosphatase level in the cirrhosis group was 131.3 and in the control 
group it was 80.1. 
 
Chart 4 
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Mean values of SGOT and SGPT were 62.81 and 58.75 respectively in the 
cirrhosis group and in the control group it was 21.90 and 20.20 respectively. 
 
Chart 5 
 
Chart 6 
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Mean value of albumin in the cirrhosis group was 3.38 and in the control group it 
was 3.97. 
 
Chart 7 
Mean value of INR (prothrombin time) in the cirrhosis group was 1.4 and in the 
control group it was 0.9. 
 
Chart 8 
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Calcium and phosphorus levels were decreased in the chronic liver disease group 
than the control group. Mean value of calcium and phosphorus in the cirrhotic 
group was 7.9 and 3.4 respectively and in the control group it was 9.7 and 3.7. 
Calcium was corrected according the albumin levels and was computed. 
 
Chart 9 
 
Chart 10 
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Parathyroid hormone was with in the normal range in both the cirrhotic group  and 
controls, but the mean value was higher in the cirrhotic group than the control 
group. 
Mean value of parathyroid hormone was 40.17 in the cirrhotic group and 33.6 in 
the control group with a P value of 0.026, which was significant. 
 
Chart 11 
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Vitamin D levels was significantly lower in the cirrhotic group than the control 
group. Mean value of vitamin D in the cirrhotic group was 23.9 and in the control 
group it was 41.5 with a P value of 0.001, which was significant. 
 
Chart 12 
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Table 2 -demographic and biochemical parameters between cirrhotic group 
and control group 
  N mean Standard deviation (SD) 
Age 
Cases 32 38.97 7.618 
Controls 10 42.50 4.301 
T.Bilirubin 
Cases 32 1.312 0.730 
Controls 10 0.880 0.092 
ALP 
Cases 32 131.38 30.880 
Controls 10 80.10 9.291 
SGOT 
Cases 32 62.81 21.650 
Controls 10 21.90 2.601 
SGPT 
Cases 32 58.75 17.678 
Controls 10 20.20 3.490 
Albumin 
Cases 32 3.381 0.209 
Controls 10 3.970 0.149 
INR 
Cases 32 1.416 0.148 
Controls 10 0.950 0.071 
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Calcium 
Cases 32 7.903 0.726 
Controls 10 9.770 0.221 
Phosphorus 
Cases 32 3.406 0.539 
Controls 10 3.770 0.206 
PTH 
Cases 32 40.175 14.826 
Controls 10 33.050 5.061 
Vitamin D3 
Cases 32 23.988 5.880 
Controls 10 41.530 2.767 
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Primary end point 
 
Low bone mineral density in the form of osteoporosis and osteopenia was noted in 
24 out of 32 patients . 8 patients out of the 32 patients in the cirrhotic group had no 
osteodystrophy. Among the control group none of the patients had low bone 
mineral density. 
Among the 24 patients with deceased bone mineral density in the cirrhotic group 2 
patients had osteoporosis (6.3%)  and 22 patients had osteopenia (68.8%)  
classified according to the WHO classification. 
There was a significant number of patients who had low bone mineral density in 
the cirrhotic group compared to the controls, with a P value of 0.001, which is 
statistically significant. 
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Table 3 
Dexa scan 
Group Total 
 Cases Controls 
N % N % N % 
Normal 8 25.0 10 100.0 18 42.9 
Osteopenia 22 68.8 0 .0 22 52.4 
Osteoporosis 2 6.3 0 .0 2 4.8 
Total 32 100.0 10 100.0 42 100.0 
 
 
Chart 13 
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Picture - 1 
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Picture - 2 
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Picture - 3 
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Among the patients with low bone mineral density in the cirrhotic group, 15 were 
male patients and 9 were female patients.  
Of the 8  patients with normal bone mineral density in the cirrhotic group, there 
was 7 male patients and  1female patient. 
Table  4 
Sex 
Dexa scan 
Total 
Normal Osteopenia 
N % N % N % 
Male 7 87.5 15 62.5 22 68.8 
Female 1 12.5 9 37.5 10 31.3 
Total 8 100.0 24 100.0 32 100.0 
 
 
Chart 14 
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Etiology of cirrhosis in the study group, who had low bone mineral density was 
alcoholic liver disease in 5 patients (20.8%), hepatitis B related cirrhosis in 8 
patients (33.3%) and cryptogenic in 11 patients (45.8%). 
In patients with normal bone mineral density the etiology was alcoholic liver 
disease in 5 patients ( 62.5%), hepatitis B related cirrhosis in 1 patient ( 12.5%) 
and cryptogenic in 2 patients (25%). 
 
Table 5 
Aetiology 
Dexa scan 
Total 
Normal Osteopenia 
N % N % N % 
Alcohol 5 62.5 5 20.8 10 31.3 
HBV related 1 12.5 8 33.3 9 28.1 
Cryptogenic 2 25.0 11 45.8 13 40.6 
Total 8 100.0 24 100.0 32 100.0 
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Chart 15 
 
All patients in the cirrhotic group with normal bone mineral density had  CTP 
stage A.  
Of the 22 patients with low bone mineral density in the cirrhosis group, 14 patients 
had a CTP class A (58.3%), 8 patients had  CTP class B ( 33.3%) and 2 patients 
had CTP class C ( 8.3%). P value for correlation of severity of cirrhosis was 0.119, 
which was not statistically significant , but could be clinically significant in view 
of the small sample size. 
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Table 6 
CTP score 
Dexa scan Total 
 Normal Osteopenia 
N % N % N % 
A 8 100.0 14 58.3 22 68.8 
B 0 .0 8 33.3 8 25.0 
C 0 .0 2 8.3 2 6.3 
Total 8 100.0 24 100.0 32 100.0 
 
 
 
Chart 16 
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Comparison of variables in patients with normal BMD and low BMD 
Average age of patients with normal bone mineral density  was 39.1 years.  
Average age of patients with low bone mineral density was 38.9 years. 
 
Chart 17 
 
Patients with low bone mineral density in the cirrhotic group were symptomatic for 
a significant longer period of time compared to the  patients with normal bone 
mineral density. Mean duration of symptoms in low bone mineral density group 
was 2.1 months and in normal bone mineral density group it was 14.8 months, with 
a P value of 0.001, which was significant. 
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Chart 18 
Bilirubin levels was lower in patients with normal bone mineral density than in 
patients with low bone mineral density. Mean bilirubin value in the low bone 
mineral density group was 1.42 and in the normal bone mineral density group it 
was 0.96, with a P value of 0.017, which was significant. 
   
Chart 19 
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Mean values of alkaline phosphatase, SGOT, SGPT and albumin were not 
significantly different in patients with low and normal bone mineral density. 
 
 
Chart 20 
 
 
 
 
Chart 21 
 
 
Chart 22 
51 
 
Mean INR in the normal bone mineral density group was 1.31 and in the low bone 
mineral density group it was 1.45, with a P value of 0.021, which was significant. 
 
Chart 23 
Mean values of calcium, phosphorus, parathyroid and  Vitamin D in patients with 
normal bone mineral density group was 7.9, 3.5, 37.5 and 25.0 respectively and in 
the low bone mineral density group it was 7.8, 3.3, 41, 23.6 respectively.  
 
Chart 24 
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 Chart 25 
 
Chart 26 
 
Chart 27 
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Table 7- Comparison of Demographic and Biochemical Parameters between 
patients with low BMD and normal BMD. 
 Dexa scan N Mean Std. Deviation P-Value 
Age 
Normal 8 39.130 5.718 
0.948 
Osteopenia 24 38.920 8.262 
Duration of 
symptoms (s) 
Normal 8 2.130 0.991 
0.001 
Osteopenia 24 14.830 7.510 
T.Bilirubin 
Normal 8 0.963 0.239 
0.017 
Osteopenia 24 1.429 0.802 
ALP 
Normal 8 121.000 27.718 
0.280 
Osteopenia 24 134.830 31.647 
SGOT 
Normal 8 56.500 18.095 
0.349 
Osteopenia 24 64.920 22.664 
SGPT 
Normal 8 48.630 8.991 
0.060 
Osteopenia 24 62.130 18.683 
Albumin 
Normal 8 3.450 0.131 
0.289 
Osteopenia 24 3.358 0.226 
INR 
Normal 8 1.313 0.189 
0.021 
Osteopenia 24 1.450 0.118 
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Calcium 
Normal 8 7.988 0.958 
0.711 
Osteopenia 24 7.875 0.654 
Phosphorus 
Normal 8 3.575 0.534 
0.315 
Osteopenia 24 3.350 0.541 
PTH 
Normal 8 37.563 13.558 
0.573 
Osteopenia 24 41.046 15.400 
Vitamin D3 
Normal 8 25.089 7.895 
0.550 
Osteopenia 24 23.621 5.203 
MELD 
Normal 8 10.250 1.165 
0.103 
Osteopenia 24 11.790 2.484 
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DISCUSSION 
Metabolic bone disease (hepatic osteodystrophy) is one the metabolic complication 
associated with cirrhosis. With improvement in management of chronic liver 
disease patients and with more number of liver transplantation being done these  
days, it is imperative to maintain a good quality of life in these patients (1),(10). One 
of the factors which cause a decrease  in quality of life, in patients with cirrhosis is 
decrease in bone mineral density, by increasing the risk of fragile fractures. But 
most of the patients with metabolic bone disease are not recognized, as there is no 
proper screening done in these patients. 
 
In our study, there was a significant number of  cirrhotic patients who had 
decreased bone mineral density. In a study from India, Joe Goerge et al (5) has 
reported  68% prevalence of low bone mineral density in chronic liver disease 
patients. Another study from Chandigarh,  Choudhary et (15) al has shown the 
prevalence of low bone mineral density in non cholestatic chronic liver disease to 
be around 80%. In our study, we had 68.8% of the cirrhotic patient to have 
osteopenia and 6.3% of the patients to have osteoporosis.  
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Lumbar spine and femur neck are the common sites to measure bone mineral 
density, as it is composed of more trabecular bone. But in patients with cirrhosis, 
due the presence of ascites measuring bone mineral density in the lumbar spine is 
controvertial. Guanabans.N et al (8) has shown that measuring bone mineral density 
in the lumbar spine is highly inaccurate giving false positive reports. In our study 
we had taken the femur neck as site of measurement to avoid false positive reports. 
 
Etiology of hepatic osteodystrophy can be multifactorial (4). In our study, we found 
that the mean values of bilirubin and  prothrombin time (3) was significantly higher 
in patients with low bone mineral density compared with those patients with 
normal bone mineral density ( P values of 0.017 and 0.02 respectively). Vitamin D 
levels were significantly low in the cirrhotic patients than the controls (P value -
0.001), but there was no significant difference in the levels between the patients 
with low bone mineral density and normal bone mineral density (P value – 0.55). 
Correlation of vitamin D levels with low bone mineral density has not been 
established in previous studies. In our study also there was no significant 
correlation of vitamin D levels between the low and normal bone mineral density 
patients. 
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Similarly no significant correlation was observed with calcium, phosphorus and 
parathyroid hormone between the low bone mineral density and normal bone 
mineral density patients. Tukeli et al (9) has also shown that there is no correlation  
with bone mineral density and calcium, albumin and GGT. 
In  our study, the common etiology of cirrhosis among patients who had low bone 
mineral density was hepatitis B (8 patients) (13), followed by alcohol ( 5 patients). 
No cause was found in 11 patients with low bone mineral density. Study by 
Choudhary et al (15) has shown the etiology of cirrhosis to be viral in 41.1% and 
alcohol in 58.2%. 
In our study the duration of symptoms in the cirrhotic group significantly 
correlated with the presence and severity of bone mineral density. Severity of 
cirrhosis had a significant correlation to the bone mineral loss. All patients with 
CTP class B and C had low bone mineral density. 2 patients in the study with CTP 
class C had osteoporosis and 8 patients with CTP class B had osteopenia (P value – 
0.119), eventhough the P value was not statistically significant it could be 
clinically significant due to small sample size of our study. But a study by Ashraful 
et al (12) has shown no relation between the severity of liver disease and bone 
mineral loss. So we would require more studies on this issue. 
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CONCLUSION 
Inference from this study done in our department include 
1. Hepatic osteodystrophy was common in people with non cholestatic 
chronic liver disease. 
2. There was a slight male predominance noted in the study. 
3. Bilirubin and prothrombin levels were significantly low in patients with 
low bone mineral density compared to patients with normal bone mineral 
density. 
4. Longer duration of symptoms in the cirrhotic patients was significantly 
related to the bone mineral loss. 
5. Severity of the liver disease was significantly related to the bone mineral 
loss. 
6. There was no correlation of vitamin D, calcium, parathyroid hormone 
levels with bone mineral loss. 
7. In view of high frequency of metabolic bone disease in patients with non 
cholestatic chronic liver disease, screening for bone mineral loss with 
DEXA scan should be done. 
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1. PBC  - Primary biliary  cirrhosis 
2. IGF  - Insulin Like Growth Factor 
3. DEXA  - Dual Energy Xray Absorpiometry 
4. IL   - Interleukin  
5. TNF  - Tumor Necrosis Factor 
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8. BMD  - Bone Mineral Density 
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10. PTH  - Parathyroid Hormone 
11. CTP  - Child Turcotte Pugh 
12. SGOT  - Serum Glutamic oxaloacetic Transaminase 
13. SGPT  - Serum Glutamic Pyruvate Transaminase 
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PROFORMA 
 
NAME OF THE PATIENT : 
AGE: 
IP NO.: 
ADDRESS: 
 
OCCUPATION: 
 
HISTORY: 
 
EXAMINATION: 
 
INVESTIGATIONS :  CBC 
                                   RFT 
                                  LFT 
                                  URINE R/E 
                                  USG ABDOMEN 
                                  PORTAL DOPPLER 
                                  VIRAL MARKERS 
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                                  CALCIUM/PO4 : 
                                  VIT. D: 
                                  PTH: 
                                  BMD: 
 
CTP SCORE: 
MELD SCORE: 
COMPLICATIONS: 
 
DIAGNOSIS: 
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Bµõ´a] uPÁÀ uõÒ 
 
 CµõãÆ Põ¢v Aµ_ ö£õx ©¸zxÁ©øÚUS Pøn¯ AÇØ] £õv¨¦hß Á¸®  
÷{õ¯õÎPÎh® C¢u B´Ä {øhö£ÖQÓx. 
 DµÀ Pµøn ÷{õ°ÚõÀ HØ£k® G¾®¦ ©õØÓ[PøÍ AÔ¢x öPõÒÁ÷u C¢u 
Bµõ´a]°ß ÷{õUP©õS®. 
 ¬iÄPøÍ AÀ»x P¸zxPøÍ öÁÎ°k® ÷£õ÷uõ AÀ»x Bµõ´a]°ß ÷£õ÷uõ u[PÍx 
ö£¯øµ÷¯õ AÀ»x Aøh¯õÍ[PøÍ÷¯õ öÁÎ°h©õm÷hõ® Gß£øu²® öu¶ÂzxU 
öPõÒQ÷Óõ®. 
 C¢u Bµõ´a]°À £[÷PØ£x u[PÐøh¯ Â¸¨£zvß ÷£¶À uõß C¸UQÓx. ÷©¾® 
}[PÒ G¢÷{µ¬® C¢u Bµõ´a]°¼¸¢x ¤ß Áõ[P»õ® Gß£øu²® öu¶ÂzxU 
öPõÒQ÷Óõ®. 
 C¢u ]Ó¨¦¨ £¶÷\õuøÚPÎß ¬iÄPøÍ Bµõ´a]°ß ÷£õx AÀ»x Bµõ´a]°ß ¬iÂß÷£õx 
u[PÐUS AÔÂUP¨£k® Gß£øu²® öu¶ÂzxU öPõÒQ÷Óõ®. 
 
Bµõ´a]¯õÍº øPö¯õ¨£®    £[÷PØ£õÍº øPö¯õ¨£® 
÷uv : 
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CONSENT 
 
DESCRIPTION: You are invited to participate in a research study on liver 
disease.   
 
PROCEDURES: : You will be asked to provide a sample of blood (6 ml ). The 
blood will be drawn from your arm . your bone mineral density will be 
measured by DEXA scan at the same time. 
 
PAYMENTS: You will not be paid to participate in this study. 
 
I, ____________________________________________ , hereby consent to 
donate a sample of my blood for the purpose of estimating calcium, 
phosphorus, vitamin D and parathormone and undergo a scan to measure my 
bone density . I have understood that this sample and the scan report will be 
used for research and the results will not be available to me. I have also 
understood that this does not involve any additional procedure 
 
Signature of the patient 
 
 Name of the patient 
 
Witness – Signature, Name and address 
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INFORMATION SHEET 
We are conducting a cross sectional study “to determine the frequency of 
metabolic bone disease in Non-cholestatic chronic liver  diseases” at 
Department of Gastroenterology, Madras Medical College . Government 
General Hospital, Chennai. 
We will be measuring bone mineral density for all the patients with Non-
cholestatic chronic liver  diseases .  Blood for Biochemical analysis will be 
drawn. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in loss of benefits to which you are otherwise entitle. 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid in 
the management or treatment. 
 
 
Signature of the Investigator          Signature of the 
Participant 
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name of the patient age sex diagnosis aetiology duration of  T.Bilirubin ALP SGOT SGPT albumin  INR calcium phosphorus PTH vitamin D3 dexa scan CTP score MELD
suresh 37 m cirrhosis alcohol 2 mts 0.8 134 42 38 3.6 1.5 9.8 2.7 31.3 40 normal A 11
vijayakumar 40 m cirrhosis alcohol 8 mts 1 98 68 57 3.4 1.4 8.4 3.9 38.6 20.9 osteopenia A 10
sajitha 45 f cirrhosis crptogenic 10 mts 0.9 142 59 63 3.1 1.5 7.4 4.4 52.5 25.4 osteopenia A 11
devaraj 48 m cirrhosis alcohol 1 mt 1.3 98 75 48 3.3 1.3 8.1 4.1 23.4 22.39 normal A 10
vellamuthu 49 m cirrhosis alcohol 24 mts 2.3 163 81 72 3.5 1.6 7.4 2.7 47.2 30.33 osteopenia B 15
selvam 40 m cirrhosis crptogenic 7 mts 1.6 198 40 38 3.6 1.4 6.9 4.4 21.5 22.47 osteopenia A 12
irudhayanathan 45 m cirrhosis hbv related 8 mts 3.9 105 54 46 2.9 1.8 9.6 2.8 4.6 8.71 osteopenia C 19
rajalaksmi 23 f cirrhosis crptogenic 9 mts 0.9 113 74 84 3.7 1.3 7.2 3.7 55.4 20.07 osteopenia A 11
sudhakar 30 m cirrhosis crptogenic 4 mts 0.8 98 32 43 3.5 1.1 7.2 3.9 32.3 15.92 normal A 9
kumar 45 m cirrhosis alcohol 10 mts 0.7 179 78 53 3.4 1.4 7.9 3.3 35.8 21.4 osteopenia A 10
appar 47 m cirrhosis hbv related 24 mts 1.2 99 45 62 3.5 1.4 7.9 3.4 39.1 27.42 osteopenia A 11
sriranjani 40 f cirrhosis crptogenic 24 mts 1 102 32 41 3.1 1.4 8.5 4 33.6 20.2 osteoporosis B 11
vannamal 38 f cirrhosis crptogenic 2 mts 0.8 94 38 47 3.6 1.5 8.1 3.9 68.7 19.2 normal A 11
annamalai 39 m cirrhosis hbv related 10 mts 3.2 116 102 93 3.4 1.6 7.9 3.6 33 20.8 osteopenia B 17
narayanaswamy 45 m cirrhosis alcohol 1 mt 1.1 147 82 63 3.3 1.5 8.8 4.1 38.5 22.5 normal A 12
dhanalaksmi 41 f cirrhosis hbv related 16 mts 1.2 134 58 64 3.4 1.4 8.6 3.4 28.2 35.6 osteopenia A 11
meganathan 42 m cirrhosis alcohol 2 mts 0.9 172 67 52 3.5 1.3 7.8 3.1 40.2 33.8 normal A 9
govindaraj 40 m cirrhosis alcohol 36 mts 2.1 181 73 53 3.3 1.5 7.9 2.7 81.1 22.7 osteopenia C 14
thangaraj 47 m cirrhosis crptogenic 10 mts 1 109 59 68 3.1 1.6 7.8 3.2 37.1 20.5 osteopenia A 12
bakthan 38 m cirrhosis hbv related 2 mts 1.3 112 62 59 3.5 1.3 6.9 3.1 33.8 23.5 normal A 11
indrani 31 f cirrhosis crptogenic 7 mts 0.8 96 47 61 3.6 1.4 7.8 2.9 52.3 25.5 osteopenia A 10
mehaboob basha 42 m cirrhosis alcohol 14 mts 0.9 165 67 62 3.5 1.3 6.6 3.5 40 18.9 osteopenia B 9
rajaiyyan 35 m cirrhosis alcohol 3 mts 0.7 113 54 39 3.3 1 7.2 3.7 32.3 23.4 normal A 9
thanunathan 43 m cirrhosis hbv related 15 mts 1.1 121 92 87 3.1 1.4 6.8 2.9 29.9 20.5 osteopenia B 11
arasani rangan 35 f cirrhosis hbv related 13 mts 1.1 132 45 49 3.6 1.5 8.7 2.4 66.8 28.6 osteopenia A 11
venkakesh 30 m cirrhosis crptogenic 24 mts 0.8 99 94 71 3.2 1.3 7.9 3.9 45.9 23.4 osteoporosis B 9
chandrasekar 50 m cirrhosis crptogenic 15 mts 0.9 124 37 41 3.4 1.3 8.1 3.3 28.7 27 osteopenia B 9
stella 33 f cirrhosis crptogenic 10 mts 0.8 156 38 32 3.5 1.4 7.8 2.9 33.7 25.6 osteopenia A 10
banumathy 26 f cirrhosis crptogenic 10 mts 1.4 118 96 90 3.3 1.5 7.8 3.1 42 20.8 osteopenia A 11
venkatesan 23 m cirrhosis crptogenic 24 mts 1.8 153 112 97 3.6 1.4 8.3 3.2 54.8 29.8 osteopenia A 12
vijayalaksmi 30 f cirrhosis hbv related 18 mts 2.1 188 65 71 2.9 1.5 7.7 3.9 34.9 22.8 osteopenia B 14
srinivasan 50 m cirrhosis hbv related 10 mts 1.6 145 42 36 3.5 1.5 8.1 2.9 48.4 27.5 osteopenia A 13
name of the patient age sex T.Bilirubin ALP SGOT SGPT albumin INR calcium phosphorus PTH Vitamin D dexa scan
senthil kumar 32 m 0.8 76 24 27 3.9 0.9 9.8 4.1 24.6 42.3 normal
jayanthi 40 f 0.9 87 22 19 4 1 10.1 3.9 28.7 40.1 normal
ramani 42 m 0.7 98 23 18 4.2 0.9 9.7 4 31.8 39.7 normal
shankar 47 m 1 65 18 23 4.1 1.1 9.8 3.7 29.8 38.9 normal
sivaiah 45 m 0.9 72 27 21 3.8 0.9 10 3.9 33.7 42.5 normal
natarajan 43 m 0.8 83 20 19 4.1 1 9.9 3.7 41.8 39.6 normal
bhuvaneswari 45 f 0.9 74 19 16 3.8 0.9 9.6 3.8 38.3 45.7 normal
kanchana 41 f 1 86 22 18 3.8 0.9 9.7 3.5 37.6 43.6 normal
sastri 44 m 0.9 77 21 24 4.1 1 9.8 3.6 32.8 37.6 normal
manoram 46 f 0.9 83 23 17 3.9 0.9 9.3 3.5 31.4 45.3 normal
